Inside the Transplantation Market: What’s Fueling a 9.3% CAGR

When an organ or tissue fails, a transplant is often the only lasting treatment. Demand for transplantation products is rising as chronic disease spreads and the technology improves. According to Grand View Research, the global transplantation market was valued at USD 15.0 billion in 2022. It is projected to reach USD 30.9 billion by 2030, a CAGR of 9.3% from 2023 to 2030.

This post covers what is pushing the market forward, what is holding it back, and how its main segments are shaping up.

Key Growth Drivers

1. A rising burden of organ failure. Serious trauma, acute illness, poor diet, alcohol use, and physical inactivity all contribute to organ failure. Diabetes and high blood pressure are leading causes of end-stage renal disease, and for those patients the options are dialysis or a kidney transplant. As these conditions become more common, the need for transplant products grows with them.
2. Technological advances and new products. Manufacturers keep releasing new tissue products, immunosuppressants, and preservation solutions. Innovation also extends to surgical technique. In April 2023, surgeons in Spain performed what was reported as the world's first robotic lung transplant. Emerging approaches such as 3D bioprinting aim to regenerate tissues and, eventually, organs. A 2020 collaboration between CollPlant Biotechnologies and United Therapeutics applies bioprinting to developing human kidneys for transplant.
3. More tissue banks and stronger government support. A growing number of tissue banks is improving access to transplant material. Governments are also investing in donation. In the U.S., the Health Resources and Services Administration (HRSA) has funded grant programs to increase donors and procedures. It also started a modernization effort for the organ procurement and transplant network in 2023, and its 2020 Hospital Organ Donor Campaign was followed by an increase in donations.
4. Strategic activity among manufacturers. Companies are expanding their portfolios through mergers, acquisitions, and collaborations. Generic launches add to this, such as Lupin's 2020 U.S. launch of generic tacrolimus, which is used to prevent organ rejection.

See the Data Before You Decide. Preview the report's trend analysis, estimates, and forecasts. Download Free Sample

Key Challenges

The organ supply gap. Demand for donor organs far exceeds supply. In 2019, about 43,201 patients in the U.S. were waiting for a kidney, but only 23,401 kidney transplants were performed. Low awareness of organ donation and religious and cultural beliefs keep many people from donating, which limits how many procedures can happen.

Infection risk and pandemic disruption. Transplant recipients take strong immunosuppressants, which leave them more vulnerable to infection. Combined with shortages of protective equipment, ICU capacity, and blood products, this contributed to a sharp fall in transplant numbers and market revenue in 2020.

Market Segmentation Overview

The report segments the market by product, application, end use, and region.

By Product

• Tissue products led in 2022 with a 57.7% share. Growth comes from procedures such as cochlear, heart valve, bone marrow, and orthopedic soft tissue transplants, along with steady new product development.
• Immunosuppressive drugs are expected to grow strongly. Recipients need them to prevent rejection, and the rise in chronic disease is increasing demand for organ replacement.
• Preservation solutions are also expected to grow significantly. Drivers include government support for stem cell research, more transplant procedures, and rising organ donation worldwide.

By Application

• Tissue transplantation is the dominant application. Skin, cornea, bone, heart valve, tendon, nerve, and vein replacements are among the most commonly performed procedures worldwide, and burn and accident cases add to demand.
• Organ transplantation is expected to grow at a lucrative rate, helped by rising procedure volumes and repeat purchases of immunosuppressants.

By End Use

• Hospitals held the largest share, 49.5% in 2022, as primary treatment centers with developed infrastructure and databases for checking organ availability.
• Transplant centers are projected to grow fastest, as rising procedure volumes and government donation initiatives drive demand for specialized centers.

By Region

• North America led with a 39.0% share in 2022. It has advanced healthcare facilities and a strong presence of major biotechnology and medical device companies, including Medtronic, Stryker, Zimmer Biomet, Arthrex, and Novartis.
• Asia Pacific is the fastest-growing region. Stem cell research for lab-grown tissues and organs is expanding there, and healthcare infrastructure is improving in countries such as India, Thailand, the Philippines, and Indonesia.

Want Numbers That Fit Your Strategy? Add countries, segments, or data points, or tailor the product definitions to your business. Customize This Report

Competitive Landscape

The market is highly fragmented, with large, mid-sized, and small vendors competing. The report names Zimmer Biomet, Medtronic, and Stryker as leading players. Other profiled companies include AbbVie, Arthrex, Novartis, 21st Century Medicine, BioLife Solutions, Teva Pharmaceuticals, and Veloxis Pharmaceuticals.

The Outlook

Growth to 2030 will depend on closing the gap between organ demand and supply. Better products, supportive government programs, and regenerative technologies like 3D bioprinting should help narrow it. Growing healthcare capacity in Asia Pacific and other emerging markets adds further opportunity.

Explore our dedicated business services:

Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today.

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today